Price
No data yet.
Social Signal Score
Analyst Ratings
24 analystsRevenue
$200.41M+131.39%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Wendy Barnes
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Employees
- 697
- Beta
- 1.67
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 0.19
Financials
Revenue
$200.41M+131.4%Net Income
$8.54M-14.7%EBITDA
$47.55M+30.6%Free Cash Flow
$80.47M+224.4%EPS (diluted)
$0.02-27.5%Shares Outstanding (diluted)
348.06M-4.0%Operating Expenses
$133.51MCash & Debt
$296.11MReturn of Capital
$1.95MRevenue by Segment (annual)
$685.09MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $796.85M | $30.44M | $0.09 |
| 2024 | $792.32M | $16.39M | $0.04 |
| 2023 | $750.26M | $-8.87M | $-0.02 |
| 2022 | $766.55M | $-32.83M | $-0.08 |
| 2021 | $745.42M | $-25.25M | $-0.06 |
| 2020 | $550.70M | $-293.62M | $-1.07 |
| 2019 | $388.22M | $66.05M | $0.12 |
| 2018 | $249.52M | $43.79M | $0.12 |
| 2017 | $157.24M | $8.84M | $0.02 |
| 2016 | $99.38M | $-7.77M | $-0.02 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.13
- Implied price
- $4.02
- Return from $2.92
- 6.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $2.00 — -31.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 22 | 27 | 32 | 37 | 42 |
|---|---|---|---|---|---|
| -2.0% | -10.3% | -6.5% | -3.3% | -0.4% | 2.1% |
| 3.0% | -5.7% | -1.7% | 1.6% | 4.6% | 7.3% |
| 8.0% | -1.1% | 3.0% | 6.6% | 9.7% | 12.5% |
| 13.0% | 3.5% | 7.8% | 11.5% | 14.8% | 17.8% |
| 18.0% | 8.0% | 12.6% | 16.5% | 19.9% | 23.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120+33.33%Social Signal Score
Mentions (6)
- Newsbusinesswire.com·12d ago·Positive
GoodRx Brings Prescription Pricing Intelligence to Google Cloud's Gemini for Healthcare SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the trusted platform for prescription access and affordability in the U.S., today announced it is a launch partner for Google Cloud's Gemini for healthcare. Through the GoodRx Model Context Protocol (MCP) integration, healthcare enterprises are able to retrieve GoodRx prescription pricing and savings information directly within Gemini for healthcar…
View source ↗ - Newsseekingalpha.com·22d ago·Neutral
GoodRx Holdings Is Going Through A Painful Transition That Will Pay Off GoodRx Holdings remains a 'buy' as shares are deeply undervalued despite recent operational headwinds and a 45% stock decline. Revenue and profits grew through 2025, but 2026 saw declines due to falling monthly active users and retail pharmacy disruptions. Strategic investments in subscriptions and Pharma Direct, especially weight loss drugs, are driving growth in new segments despite short-term margin pressure.
View source ↗ - Newsreuters.com·54d ago·Negative
Amazon, GoodRx target US prescription subscribers as health insurance coverage slips Amazon.com , GoodRx and other companies offering online subscriptions that charge a flat fee for prescription drugs and other health services are reaping the benefits of Americans looking to combat rising costs and dwindling health insurance options.
View source ↗ - Newspymnts.com·79d ago·Positive
GoodRx Covers Whole Households and Pets in New Prescription Plan Prescription platform GoodRx has launched a new plan that covers a primary member and up to four dependents, including children, adult family members and pets, the company said in a Thursday (Sept. 3) press release.
View source ↗ - Newsreuters.com·80d ago·Negative
GoodRx offers health subscription for families, to launch as employee benefit in 2027 GoodRx, a prescription drug savings site, announced on Thursday a family healthcare subscription for access to common medical services and over 250 medications, and it plans to launch the program as part of employer health benefits in 2027.
View source ↗ - Newsseekingalpha.com·102d ago·Positive
GoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope GoodRx has rebounded from $2.50 per share, showing renewed growth momentum and improved consumer traction. New offerings have contributed to GDRX's recent positive developments, but the stock's rapid appreciation reflects these improvements. I remain marginally more positive, yet GDRX still presents considerable risk, warranting a continued neutral rating.
View source ↗
Earnings
Mon, Nov 23(today)
Consensus estimate $0.07 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$0.08 vs $0.08beat
- Wed, May 6$0.07 vs $0.07beat
- Wed, Feb 25$0.09 vs $0.09beat
- Tue, Nov 4$0.08 vs $0.09miss
- Wed, Aug 6$0.09 vs $0.10miss
- Wed, May 7$0.09 vs $0.09beat
Estimates and results for GDRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GDRX officers and directors.
- Bought
- —
- Sold
- $8.1m
0 trades
13 trades
- Francisco Partners Iv, L.p.sold
- Francisco Partners Iv, L.p.sold
- Francisco Partners Iv, L.p.sold
- Francisco Partners Iv, L.p.sold
- Francisco Partners Iv, L.p.sold
- Francisco Partners Iv, L.p.sold
- Francisco Partners Iv, L.p.sold
- Francisco Partners Iv, L.p.sold
87 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Anthony Gonzalezhouse · OH16 · disclosed Apr 23, 2021 (29d later)Buy$100,001 - $250,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
